MVP feels the luck of the Irish
Medical Developments International (ASX: MVP) announced this week it received final approval from the Health Products Regulatory Authority of the Republic of Ireland to market and sell its inhaled pain-relief product Penthrox. The company said the approval gives MVP’s partner in Ireland and the United Kingdom, Galen, the opportunity to sell Penthrox effective immediately. Shares in MVP jumped following the announcement, and closed up 14.6% for the week. We own MVP in the investment portfolio.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
Already have an account? Sign in here
Advertisement
Wilson Asset Management has a track record of making a difference for shareholders and the community for more than 20 years. As the investment manager for eight leading LICs – WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB), WAM Microcap (ASX: WMI), WAM Alternative Assets (ASX: WMA), WAM Strategic Value (ASX: WAR), WAM Research (ASX: WAX) and WAM Active (ASX: WAA) – Wilson Asset Management invests over $5.4 billion on behalf of more than 130,000 retail investors.
Wilson Asset Management created and is the lead supporter of the first listed investment companies to deliver both investment and social returns: Future Generation Australia (ASX: FGX) and Future Generation Global (ASX: FGG).
1 topic
1 stock mentioned
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
Paul Moore's stock to buy and hold for the next 25 years
Livewire Markets
Equities
A contrarian assessment of Macquarie Group
Leithner & Company Ltd
Equities
It won't get any better from here for Aussie banks
Livewire Markets